Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.
about
Obesity and cancer: mechanistic insights from transdisciplinary studiesAdverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Treatment and prevention of bone complications from prostate cancer.Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.Contemporary therapeutic approaches targeting bone complications in prostate cancerForeign body granulomas induced by intramuscular leuprorelin acetate injection for prostate cancer: clinical mimics of soft tissue sarcoma.Osteoporosis in men: a review.Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseObesity and prostate cancer: weighing the evidence.Leuprorelin depot injection: patient considerations in the management of prostatic cancerEmerging therapies to prevent skeletal morbidity in men with prostate cancer.Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.Osteoporosis and cancerIs high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate CancerEvidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate.Leuprolide acetate: pharmaceutical use and delivery potentials.Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.Clinical management of obese patients with cancer.Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials.Body mass index and prognostic markers at radical prostatectomy.The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.Prostate cancer treated with androgen deprivation therapy has consequences for bone.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Acute Testosterone Deficiency Alters Adipose Tissue Fatty Acid Storage.A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
P2860
Q26786829-C902A719-1BB8-4D05-B40B-F4F52333C4C2Q33977523-085BC8FF-B047-4709-93E2-4CC77E9D4866Q34441944-C7564439-7A8A-4384-B385-55DD18B35A41Q34617851-4ABB4500-18D0-4221-973D-54D15CEEA264Q34960778-022B3A39-8D47-4454-9946-5D10670C8A30Q35416154-EDD2240F-DFF6-49D1-8B1C-36BFB08121B9Q35755160-45BB9FEB-BE95-4E00-9C7B-5E840D8C4B33Q35931460-B1538CC4-2EE9-4F9B-B402-F4F0F46BA2F0Q36685022-5BA6946F-140E-4221-AD9F-2C86E306C384Q36823588-D9A6EB97-4E9B-4D96-BC4A-6875C90C6543Q36910469-5A5D7CD4-BAAA-4BD8-84E7-D44B70BAE644Q36931173-9DACAB23-56A6-45A9-B677-F445D3B48D36Q37198504-27EB9E9C-6C14-405E-B434-B914216F92EBQ37606746-27E9141F-5CF3-4411-AFF5-DE894B998D80Q37636973-E0371151-F795-4809-A303-0C27CA3792CAQ37672477-FFA37FF7-610E-4EE7-8ED3-BBFE02CDB0EEQ37809569-3B89213E-27CD-4321-8C5F-3A29E79BE42DQ37984084-EC86F288-0788-4604-B309-597E6B120DDBQ38067916-84FF6033-EE7C-4665-9AF4-0B0B7D367770Q38121736-955826DA-A777-4AE5-BA62-DFBDA6165294Q38998655-00DD8D2F-0CDC-466F-9C9C-4701EF81F699Q39027934-937B3319-9FB9-4C4D-A58F-3ACD70EDA32DQ40988056-A9B3A5A7-6D1F-4A57-AB99-52339ADEA74AQ43638078-0E85DF7B-41BE-48D7-AFCE-ABD3DD26ADD4Q44403298-64B171AA-426A-4DAF-B802-9F33399AE18AQ46522792-B78A84DE-77B1-47E4-9E88-C4FED02B244DQ46812033-2E4C9838-986B-4C96-8641-56B2BBF508C5Q48381608-DAE583C4-E5C9-48DE-BECF-918EE42446A9Q49971559-DC77E16D-EB3B-4E64-83F8-B14893E9D3B9Q50928850-DD1D1B51-92B1-49B2-B0D7-D78AAA117FA7Q53571610-0CED546C-08F1-4AEB-8884-C6BD36B68806Q53798282-7841DEEF-39C6-4D09-BD24-A562EED226B9
P2860
Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Obesity and sex steroids durin ...... treatment for prostate cancer.
@ast
Obesity and sex steroids durin ...... treatment for prostate cancer.
@en
Obesity and sex steroids durin ...... treatment for prostate cancer.
@nl
type
label
Obesity and sex steroids durin ...... treatment for prostate cancer.
@ast
Obesity and sex steroids durin ...... treatment for prostate cancer.
@en
Obesity and sex steroids durin ...... treatment for prostate cancer.
@nl
prefLabel
Obesity and sex steroids durin ...... treatment for prostate cancer.
@ast
Obesity and sex steroids durin ...... treatment for prostate cancer.
@en
Obesity and sex steroids durin ...... treatment for prostate cancer.
@nl
P2860
P1476
Obesity and sex steroids durin ...... treatment for prostate cancer.
@en
P2093
Matthew R Smith
P2860
P304
P356
10.1158/1078-0432.CCR-06-2086
P407
P577
2007-01-01T00:00:00Z